This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

Buspirone in the Management of Anxiety and Irritability in Children With Pervasive Developmental Disorders: Results of an Open-Label Study

Jan K. Buitelaar, Rutger Jan van der Gaag, and Joost van der Hoeven

Published: February 15, 1998

Article Abstract

Background: We evaluated the efficacy and safetyof buspirone in the management of anxiety and irritability inchildren with pervasive developmental disorders (PDD).

Method: Twenty-two subjects, 6 to 17 years old,with DSM-III-R diagnosed PDD-NOS (N=20) or autistic disorder(N=2), were included. They were treated with buspirone in dosagesranging from 15 to 45 mg/day in an open-label trial lasting 6 to8 weeks. Responders continued buspirone treatment and werefollowed up for up to 12 months.

Results: Nine subjects had a marked therapeuticresponse and 7 subjects a moderate response on the ClinicalGlobal Impressions (CGI) scale after 6 to 8 weeks of treatment.Side effects were minimal, except for 1 patient who developedabnormal involuntary movements.

Conclusion: These results suggest that buspironemay be useful for treating symptoms of anxiety and irritabilityin children with PDD.

Volume: 59

Quick Links:

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF